跳至主要内容
临床试验/NCT07461909
NCT07461909招募中不适用

Comparison of Patient Satisfaction, Convenience and Tolerability Between Two Vaginal Progesterone Formulations During Frozen Embryo Transfer

Instituto Valenciano de Infertilidade de Lisboa1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2024年11月8日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
400
试验地点
1
主要终点
Compare the patients' satisfaction, convenience and tolerability of two common vaginal progesterone formulations: soft capsules versus pessaries

研究概览

简要总结

The goal of this observational study is to compare two commonly used vaginal progesterone formulations - soft capsules versus pessaries - in women undergoing frozen embryo transfer (FET). The main question it aims to answer is:

- Do soft vaginal progesterone capsules provide similar or better patient satisfaction, convenience, and tolerability compared with vaginal progesterone pessaries during preparation for frozen embryo transfer?

Participants undergoing FET who are prescribed vaginal progesterone as part of their endometrial preparation and luteal phase support will use one of the two formulations and complete patient-reported assessments regarding satisfaction, convenience, and tolerability. The study will also measure serum progesterone levels on the day of embryo transfer and evaluate pregnancy outcomes, including clinical pregnancy and live birth rates.

详细描述

Over the past few decades, assisted reproductive technology (ART) treatments have seen their protocols updated by advances in cryopreservation methods, leading to the mainstream use of the frozen embryo transfer (FET) strategy (Nagy, Shapiro, & Chang, 2020). FET protocols are generally subdivided in either natural cycle (NC-FET) or artificial cycle (AC-FET), with several centers preferring the latter due to its flexibility in scheduling and ease of monitoring. Nonetheless, previous reports positing that AC-FET may be associated with an increased risk of miscarriage and hypertensive disorders during pregnancy have put this preference into question (Roelens, et al., 2022). Having said that, the natural proliferative phase frozen embryo transfer protocol (NPP-FET) has recently be proposed as a strategy which potentially allows for easier cycle scheduling while potentially maintaining the benefits of the natural cycle in terms of safer pregnancy outcomes (Godinho, Soares, & Ribeiro, 2021). Both AC-FET and NPP-FET protocols rely immensely on the use exogenous progesterone for luteal phase support (LPS), with the vaginal route being the most common in Europe due to its ease of use compared to intramuscular or subcutaneous alternatives.

Progesterone is a natural hormone produced mainly by the theca cells of the corpus luteum. When supplemented vaginally, endometrial progesterone concentrations reach a steady-state within 5 hours after administration, while serum progesterone levels remain elevated for about 48 hours with prolonged bioavailability (Bulletti, et al., 1997). In a systematic review of 18 randomized clinical trials comparing vaginal preparations for LPS, all tested preparations seemed to be equally effective and safe for assisted reproductive technology cycles (Child, Leonard, Evans, & Lass, 2018). However, studies assessing patient satisfaction are lacking (Beltsos, et al., 2014). Hence, the main objective of this study is to assess the level of satisfaction as well as understand the convenience and tolerability of two of the most common vaginal LPS formulations (soft capsules versus pessaries). The study will compare satisfaction levels, convenience and tolerability, serum progesterone levels on the FET day and pregnancy rates between the two therapeutic formulations.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 48 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Age: ≥18 and <49 years old;
  • Body Mass Index (BMI) ≥18.5 Kg/m2 and <30 Kg/m2;
  • Planned for single blastocyst stage transfer;
  • Has been prescribed two vaginal 200mg soft capsules or one 400mg pessary of progesterone, each 12hours before and after FET;
  • Either AC-FET or NPP-FET.

排除标准

  • Women who have previously enrolled in this study;
  • Those unable to comprehend the investigational nature of the proposed study;
  • Rank of FET>3;
  • Use of oral/injectable corticoids.

研究组 & 干预措施

Cohort 1 - vaginal progesterone soft capsules

Women undergoing FET who receive soft vaginal progesterone capsules (micronized progesterone 200 mg x 2 capsules every 12 h = 400 mg/12h) for endometrial preparation/luteal support as per routine care.

干预措施: Vaginal progesterone soft capsules (Other)

Cohort 2 - vaginal provesterone pessaries (ovules)

Women undergoing FET who receive vaginal progesterone pessaries (400 mg x 1 pessary every 12 h) for endometrial preparation/luteal support as per routine care.

干预措施: Vaginal progesterone pessaries (Other)

结局指标

主要结局

Compare the patients' satisfaction, convenience and tolerability of two common vaginal progesterone formulations: soft capsules versus pessaries

时间窗: 5 days after starting progesterone supplementation

Satisfaction levels, convenience and tolerability will be collected using a GDPR compliant online survey tool, filled by participants

次要结局

  • Serum Progesterone(P4) level(5 days after starting progesterone supplementation)
  • Clinical pregnancy rates(7 - 8 weeks of gestational age)
  • Livebirth rates(Livebirth after 22 completed weeks of gestational age)

研究者

发起方
Instituto Valenciano de Infertilidade de Lisboa
申办方类型
Network
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验